Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-133-9 | CAS number: 78-69-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- No data
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Only very short publication available, but experimental result consistent with good scientific knowledge.
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- publication
- Title:
- The absorption, distribution and excretion of linalool in the rat
- Author:
- DV Parke, KHM Quddusar Rahman and R Walker
- Year:
- 1 974
- Bibliographic source:
- Biochemical Society Transactions 2:612–615
Materials and methods
- Objective of study:
- absorption
- distribution
- excretion
- metabolism
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 417 (Toxicokinetics)
- Deviations:
- yes
- Remarks:
- number and sex of animals is not specified
- Principles of method if other than guideline:
- 1,2[14C]linalool was administered in male Wistar rats intragastrically and intraperitoneally in this study.
Experiment 1: After intragastric administration of 500 mg/kg bw, urine, faeces and expired air were collected and measured at several intervals over a 72 hours period. Radioactivity was determined. At the end of the experiment, residual radioactivity in brain, lung, liver, heart, spleen, gastro-intestinal tract, kidney, skin and skeletal muscle was determined.
Experiment 2: In this experiment intraperitoneal administration was used to determine if biliary excretion occurred. Bile was collected at several intervals after exposure of 2 rats and radioactivity was determined.
Experiment 3: In this experiment one rat was intraperitoneally exposed. Bile from this treated animal was introduced into the duodenum of a second animal. Bile of this animal was then collected. Presence of radioactivity was indicative of enterohepatic circulation. - GLP compliance:
- no
Test material
- Reference substance name:
- Linalool
- EC Number:
- 201-134-4
- EC Name:
- Linalool
- Cas Number:
- 78-70-6
- Molecular formula:
- C10H18O
- IUPAC Name:
- 3,7-dimethylocta-1,6-dien-3-ol
- Details on test material:
- - Name of test material (as cited in study report): Linalool
- Substance type: Tertiary alcohol
- Locations of the label (if radiolabelling): Positions 1 and 2 of linalool
- Specific activity (if radiolabelling):
Experiment 1: 10 uCi
Experiment 2 & 3: 1 uCi
Constituent 1
- Radiolabelling:
- yes
- Remarks:
- 14C
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 12 weeks
- Individual metabolism cages: yes
Administration / exposure
- Route of administration:
- other: intragastric (exp. 1) and intraperitoneal (exp. 2 & 3)
- Vehicle:
- propylene glycol
- Details on exposure:
- VEHICLE
- Concentration in vehicle:
Experiment 1: 25% (w/v)
Experiment 2 & 3: 10% (w/v) - Duration and frequency of treatment / exposure:
- Single administration
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Experiment 1: 500 mg/kg bw
Experiment 2 & 3: 20 mg/animal
- No. of animals per sex per dose / concentration:
- Experiment 1: Not indicated
Experiment 2 & 3: 2 male animals - Details on dosing and sampling:
- PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
Experiment 1:
- Tissues and body fluids sampled: urine, faeces, expired air
- Time and frequency of sampling: collected at intervals over a 72h period
- Tissues and body fluids sampled at end of experiment (distribution): brain, lung, liver, heart, spleen, gastro-intestinal tract, kidney, skin and skeletal muscle
Experiment 2:
- Tissues and body fluids sampled: bile
- Time and frequency of sampling: at intervals over a 6h and 11h period (1 animal for each period)
Experiment 3:
- Tissues and body fluids sampled: bile (from one of the two animals)
METABOLITE CHARACTERISATION STUDIES
Experiment 2:
- Tissues and body fluids sampled: bile
- Time and frequency of sampling: at intervals over a 6h and 11h period (1 animal for each period)
Experiment 3:
- Tissues and body fluids sampled: faeces, bile
- Time and frequency of sampling: at intervals over a 12h period
- From how many animals: 1 - Statistics:
- Not relevant
Results and discussion
- Preliminary studies:
- Not relevant
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Experiment 1: at least 85% of linalool is absorbed (detected in urine and expired air) after 72 hours
- Details on distribution in tissues:
- Experiment 1 (in total: 3% of dose) after 72 hours:
- Liver: 0.5%
- Gut: 0.6%
- Skin: 0.8%
- Skeletal muscle: 1.2%
- Other organs: insignificant amounts of radioactivity
- Details on excretion:
- Experiment 1: approx. 100% of the administered dose is excreted (urine, faeces, expired gas) after 72 hours.
- Expired air: 23%
- Urine: approx. 60%
- Faeces: approx. 15% (delayed, possible biliary excretion)
Experiment 2:
- Bile: more than 25% of the ip dose detected after 11 hours
Experiment 3:
- Bile: 2.5% of ip dose detected in second rat after 12 hours
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- Experiment 2: No free linalool, but only polar conjugates were detectable in bile (partially hydrolysed by beta-glucuronidase and to a greater extent by a mixture of beta-glucuronidase and sulphatase).
Experiment 3: Biliary conjugates detected in bile, non-polar ether-extractable metabolites (5% of dose) detected in faeces.
Any other information on results incl. tables
Experiment 3: Assuming 25% of the ip dose appeared in bile of first animal and also that 25% of conjugates appeared in bile of second animal, it was calculated that 40% of the biliary conjugates are hydrolysed and reabsorbed on the first pass. Extensive enterohepatic circulation is therefore possible. Part of the absorbed linalool is thus excreted by faeces.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): other: Complete absorption, no bioaccumulation, rapid excretion, glucuronide- and sulfate conjugates, enterohepatic recirculation
Under the conditions of this study, linalool (500 mg/kg bw) was rapidly and completely absorbed in rats after oral (gavage) administration. After 72h, 3% of the dose remained in tissues. Intraperitoneal administration (20 mg/animal) showed that at least 25% of the dose is excreted in bile (faeces). Enterohepatic circulation was detected and biliary conjugates and non-polar ether-extractable metabolites (in faeces) are formed. These are glucuronide- and sulfate conjugates. Within 72 h, 97% are excreted with the majority (ca. 80%) after 36h and 95% after 48h. 60% of administered radioactivity occured in urine, 15% in faeces and 25% in expired air. - Executive summary:
14C labelled linalool was administered orally (gavage) and intraperitoneally to male Wistar rats in this study. For the first exposure route a dose of 500 mg/kg bw was used, for the second route this was 20 mg/animal.
Experiment 1: After intragastric administration, urine, faeces and expired air were collected and measured at several intervals over a 72 hours period. Radioactivity was determined. At the end of the experiment, residual radioactivity in brain, lung, liver, heart, spleen, gastro-intestinal tract, kidney, skin and skeletal muscle was determined.
Experiment 2: In this experiment intraperitoneal administration was used to determine if biliary excretion occurred. Bile was collected at several intervals up to 11 hours after exposure of 2 rats and radioactivity was determined.
Experiment 3: In this experiment one rat was intraperitoneally exposed. Bile from a this treated animal was introduced into the duodenum of a second animal. Bile of this animal was then collected. Presence of radioactivity was indicative of enterohepatic circulation.
Under the conditions of this study, linalool (500 mg/kg bw) was rapidly and completely absorbed in rats after oral (gavage) administration. After 72 h, 3% of the dose could be detected in tissues. Intraperitoneal administration (20 mg/animal) showed that ca. 25% of the dose is excreted in bile (faeces). Enterohepatic circulation is possible and that biliary conjugates and non-polar ether-extractable metabolites (faeces) are formed. These are likely glucuronide and sulfate conjugates. Excretion is rapid; within 36h 80% of radioactivity and within 48h 95% of radioactivity had been excreted. After 72h, majority was excreted via urine (60% of administered radioactivity), faeces (15%), expired air (23%).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.